Orthocell Limited (ASX:OCC) Reports First US Remplir™ Sales Revenue
Orthocell (ASX:OCC) records first US sales revenue from Remplir™ nerve repair product, marking a significant milestone in US expansion.
Category: ASX-OCC
Orthocell Limited
Orthocell Limited (ASX:OCC) Accelerates US Remplir™ Sales Rollout with 12 Distributors
Orthocell Limited (ASX:OCC) accelerates Remplir™ sales rollout with 12 US distributors, surpassing targets and setting the stage for first sales.
Orthocell Limited (ASX:OCC) Gains Thai FDA Approval for Remplir™
Orthocell (ASX:OCC) receives Thai FDA approval to launch Remplir™, expanding into the US$84 million nerve repair market.
Orthocell Limited (ASX:OCC) Receives FDA Clearance for Remplir™
Orthocell (ASX:OCC) secures FDA clearance for Remplir™, enabling entry into the US $1.6 billion nerve repair market.
Orthocell Limited (ASX:OCC) Completes First Sales of Striate+ in DACH Region
Orthocell Limited (ASX:OCC) achieves first sales of its Striate+ product in the DACH region, marking a significant expansion in its European markets.
Orthocell Limited (ASX:OCC) Receives Singapore Regulatory Approval for Striate+
Orthocell Limited (ASX:OCC) secures Singapore’s regulatory approval for Striate+, boosting its global market expansion and sales growth.